

Application No. 09/852,209  
Reply dated July 16, 2004  
Response to Office Action dated January 16, 2004

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-35. (canceled)

36. (currently amended) A method of stimulating growth of connective tissue or wound healing in a mammal, said method comprising administering to said mammal an effective growth stimulating amount of a polypeptide comprising ~~an amino acid sequence having at least 85% identity with SEQ ID NO:3 or SEQ ID NO:7, or a fragment or analog thereof having the biological activity of PDGF C, or a polypeptide produced by expression of a polynucleotide comprising a polynucleotide sequence of having at least 85% identity with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, or of a polynucleotide which hybridizes under stringent conditions with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6.~~

37-45. (canceled)

46. (currently amended) A method of promoting fibroblast mitogenesis in a mammal, comprising the step of administering to said mammal an effective fibroblast mitogenesis promoting amount of a polypeptide comprising an amino acid sequence having ~~at least 85% identity with~~ at least amino acid residues 230 to 345 of SEQ ID NO:3 or of SEQ ID NO:7, ~~or a polypeptide produced by expression of a polynucleotide comprising a polynucleotide sequence of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6.~~

47. (currently amended) A method of promoting fibroblast mitogenesis in a mammal, comprising administering to said mammal an effective ~~fibroblast~~ ~~frbreblast~~ mitogenesis promoting amount of a ~~polypeptide comprising an amino acid sequence having at least 85% identity with SEQ ID NO:3 or SEQ ID NO:7, or a fragment or analog thereof having the biological activity of PDGF C, or a polypeptide produced by expression of a polynucleotide comprising a~~

Reply dated July 16, 2004

Response to Office Action dated January 16, 2004

polynucleotide sequence of having at least 85% identity with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, or of a polynucleotide which hybridizes under stringent conditions with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6.

48. (currently amended) A method of inducing PDGF alpha alpha receptor activation, comprising the step of adding a PDGF alpha-receptor stimulating amount of a polypeptide comprising an amino acid sequence of having at least 85% identity with at least amino acid residues 230 to 345 of SEQ ID NO:3 or of SEQ ID NO:7.

49. (currently amended) A method of inducing PDGF alpha receptor activation, comprising the step of adding a PDGF alpha-receptor stimulating amount of a polypeptide comprising an amino acid sequence having at least 85% identity with SEQ ID NO:3 or SEQ ID NO:7, or a fragment or analog thereof having the biological activity of PDGF C, or a polypeptide produced by expression of a polynucleotide comprising a polynucleotide sequence of having at least 85% identity with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, or of a polynucleotide which hybridizes under stringent conditions with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6.

50-58. (canceled)

59. (currently amended) A method of promoting angiogenesis in a bird or mammal, said method comprising administering to said bird or mammal an effective angiogenesis promoting amount of a polypeptide comprising a sequence of amino acids having at least 85% identity with at least amino acid residues 230 to 345 of SEQ ID NO:3 or of SEQ ID NO:7.

60. (Original) A method according to claim 59, wherein said polypeptide is administered in the form of a dimer.